参附注射液联合西药治疗慢性心力衰竭的疗效及安全性分析  

作　　者：王璞[1] 王琦[1] 李涤病[1] 

机构地区：[1]浙江省宁波市第六医院心血管内科,315040

出　　处：《浙江临床医学》2018年第6期1079-1080,1083,共3页Zhejiang Clinical Medical Journal

摘　　要：目的探讨参附注射液联合西药治疗慢性心力衰竭的疗效及安全性。方法选自2015年6月至2017年6月收治的86例慢性心力衰竭患者，采取随机数字表将其分成两组，每组各43例。两纽患者均给予常规西药治疗，观察组联合给予参附注射液治疗，连续治疗12周后对两组患者进行疗效评估，同时统计治疗过程中出现的不良反应情况。结果观察组治疗总有效率为88．37％（38／43），与对照组的62．79％（27／43）相比显著上升（p〈0．05）。两组治疗后6min步行距离均较治疗前明显增加，Lee心衰积分、血浆NT-proBNP水平均较治疗前明显降低（P〈0，05）；观察组治疗后6min步行距离明显高于对照组，Lee心衰积分、血浆NT-proBNP水平明显低于对照组（P〈0．05）。两组治疗后LVEF均较治疗前明显升高，LVEDD、LVESD均较治疗前明显降低（P〈0．05）；观察组治疗后LVEF明显高于对照组，LVEDD、LVESD明显低于对照组（P〈0．05）。观察组不良反应发生率为11．63％（5／43），与对照组的34．88％（15／43）相比显著降低（P〈0．05）。结论参附注射液联合西药治疗慢性心力衰竭疗效显著，且无严重不良反应，疗效确切且安全性高，值得推广应用。Objective To investigate the efficacy and safety of Shenfu injection combined with western medicine in the treatment of chronic heart failure. Methods 86 patients with chronic heart failure were selected in our hospital from June 2015 to June 2017. They were divided into two groups by random number table, 43 cases in each group. Two groups of patients were given conventional western medicine treatment, the observation group was given Shenfu injection treatment, after 12 weeks of continuous treatment, the efficacy of two groups of patients were evaluated, and the adverse reactions during treatment were statistically analyzed. Results The total effective rate of treatment in the observation group was 88.37% （ 38/43 ） , which was significantly higher than that of the control group （ 27/43 ） （ P〈0.05 ） . The two groups after treatment 6min walking distance increased significantly than before treatment, the levels of plasma NT-proBNP, Lee heart failure score were significantly lower than that before treatment （ P〈0.05 ） ; the observation group after treatment 6min walking distance was significantly higher than the control group, the levels of plasma NT- proBNP, Lee heart failure score significantly lower than that of control group （P〈0.05） . After treatment, LVEF in two groups increased significantly compared with those before treatment. LVEDD and LVESD were significantly lower than those before treatment （P〈0.05） . After treatment, LVEF was significantly higher in the observation group than in the control group, LVEDD and LVESD were significantly lower than those in the control group （ P〈0.05 ） . The incidence of adverse reactions in the observation group was 11.63% （ 5/43 ） , which ＂was significantly lower than that of the control group （ 15/43 ） （ P〈0.05 ） . Conclusion Shenfu injection combined with western medicine is effective in treating chronic heart failure, and has no serious side effects. It is effective and safe, and is worthy of popularization and app

关 键 词：参附注射液 慢性心力衰竭 

分 类 号：R541.61[医药卫生—心血管疾病]